Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Cancer Genetics, Inc. Merger (Tables)

3 Months Ended

Mar. 31, 2021

The following details the preliminary allocation of the purchase price consideration:

	2021
Assets acquired:
Cash and equivalents	$	30,163
Accounts receivable		705
Other current assets		806
Intangible assets		9,500
Fixed assets		416
Goodwill		22,164
Long-term prepaid expenses and other assets		1,381
Total assets acquired	$	65,135

Liabilities assumed:
Accounts payable and accrued expenses	$	3,258
Obligation under operating lease		198
Obligation under finance lease		106
Deferred revenue		1,293
Income taxes payable		360
Total liabilities assumed	$	5,215

Net assets acquired:	$	59,920

The following presents the unaudited pro forma combined financial information as if the Merger had occurred as of January 1, 2020:

	March 31, 2021			March 31, 2020
	For the three months ended
	March 31, 2021			March 31, 2020
Total revenues:	$	1,841		$	1,594
Net loss	$	(6,495	)	$	(3,152	)
Pro forma loss per common share, basic and diluted	$	(.21	)	$	(.11	)
Pro forma weighted average number of common shares outstanding, basic and diluted		28,985			28,847